CBIS Appoints Dr. Robert Melamede, Ph.D., Former Chairman of the Biology Department at University of Colorado, Colorado Springs, As President & CEO

SAN FRANCISCO--(BUSINESS WIRE)-- Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce the appointment of Dr. Robert J. Melamede, Ph.D., as President & CEO, replacing Steven W. Kubby in that position. Mr. Kubby will remain as a Director and the company is in discussions with him about his future role.

Dr. Melamede has previously served as the Chief Science Officer of Cannabis Science Inc, and will continue in that capacity as well. Dr. Melamede retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach.

Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Advisory Board of The Journal of the International Association for Cannabis as Medicine, and the Scientific Advisory Board Medical of the Marijuana Policy Advocacy Project, as well as the Scientific Advisory Board of Americans for Safe Access. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.

The global market for oral cannabis medications has been recently estimated at almost $6 billion annually. Cannabis Science proprietary delivery systems, which insure rapid absorption with prolonged blood levels of active drug, are expected to give the company's products a competitive edge worldwide.

About Cannabis Science, Inc. 
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.